CHAAN S NG to Kidney Neoplasms
This is a "connection" page, showing publications CHAAN S NG has written about Kidney Neoplasms.
Connection Strength
1.135
-
Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. AJR Am J Roentgenol. 2010 Jan; 194(1):166-71.
Score: 0.136
-
Imaging and staging of transitional cell carcinoma: part 2, upper urinary tract. AJR Am J Roentgenol. 2009 Jun; 192(6):1488-93.
Score: 0.131
-
Renal cell carcinoma: diagnosis, staging, and surveillance. AJR Am J Roentgenol. 2008 Oct; 191(4):1220-32.
Score: 0.125
-
Radiologic diagnosis and staging of renal and bladder cancer. Semin Roentgenol. 2006 Apr; 41(2):121-38.
Score: 0.105
-
Conditional survival of patients with small renal masses undergoing active surveillance. BJU Int. 2019 03; 123(3):447-455.
Score: 0.062
-
Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. Eur Urol. 2016 05; 69(5):866-74.
Score: 0.051
-
Targeting hypoxia-inducible factor-1a (HIF-1a) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget. 2014 Nov 15; 5(21):10280-92.
Score: 0.048
-
Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int. 2014 Mar; 113(3):376-82.
Score: 0.045
-
Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol. 2013 Oct; 36(5):450-4.
Score: 0.044
-
Curability of poor-risk metastatic sarcomatoid renal cell carcinoma with the combination of gemcitabine, 5-fluorouracil, and interferon-alfa: a case report of a 55-year-old man with a 10-year complete remission. Clin Genitourin Cancer. 2013 Sep; 11(3):370-3.
Score: 0.043
-
A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol. 2012 Dec; 62(6):1013-9.
Score: 0.041
-
Evaluation of treatment response in patients with metastatic renal cell carcinoma: role of state-of-the-art cross-sectional imaging. Curr Urol Rep. 2012 Feb; 13(1):70-81.
Score: 0.039
-
Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report. Clin Genitourin Cancer. 2011 Dec; 9(2):137-9.
Score: 0.038
-
Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol. 2011 Mar 10; 29(8):e203-5.
Score: 0.036
-
Significance of upper urinary tract urothelial thickening and filling defect seen on MDCT urography in patients with a history of urothelial neoplasms. AJR Am J Roentgenol. 2010 Oct; 195(4):959-65.
Score: 0.036
-
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer. 2010 Jan 01; 116(1):57-65.
Score: 0.034
-
Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease. Radiographics. 2009 May-Jun; 29(3):741-54; discussion 755-7.
Score: 0.033
-
A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol. 2008 Sep; 180(3):867-72; discussion 872.
Score: 0.031
-
CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma. AJR Am J Roentgenol. 2007 Aug; 189(2):378-85.
Score: 0.029
-
Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer. 2006 Nov 01; 107(9):2254-61.
Score: 0.027